Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal ...

Chewable tablets are a versatile dosage form offering several advantages including oral drug delivery without the need for water, ease of swallowing, the stability advantages of solid dosage forms, ...

A case study reviews the reformulation and scale up of high drug load prototype using wet granulation process for a model formulation. v_kurashev/shutterstock.com The reformulation of a 100-mg tablet ...

BeOne Medicines recently announced that the European Commission approved a new film-coated tablet formulation of BRUKINSA (zanubrutinib) for all existing indications, halving the required daily pill ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

Patients with Graves disease who taper methimazole to a maintenance dose of 1.25 mg/day before discontinuing the drug experience improved remission rates compared to those on higher doses.

CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to address major limitations of ...

The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...

BASEL, Switzerland--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use ...